SG Americas Securities LLC Raises Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)

SG Americas Securities LLC increased its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 57.7% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 22,498 shares of the biopharmaceutical company’s stock after acquiring an additional 8,228 shares during the period. SG Americas Securities LLC’s holdings in Sage Therapeutics were worth $122,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its position in Sage Therapeutics by 66.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock worth $85,000 after acquiring an additional 4,672 shares during the period. Creative Planning purchased a new position in shares of Sage Therapeutics during the third quarter worth $88,000. Quest Partners LLC boosted its position in shares of Sage Therapeutics by 56.3% during the third quarter. Quest Partners LLC now owns 18,381 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 6,618 shares during the period. Intech Investment Management LLC purchased a new position in shares of Sage Therapeutics during the third quarter worth $146,000. Finally, Erste Asset Management GmbH purchased a new position in shares of Sage Therapeutics during the third quarter worth $208,000. 99.22% of the stock is currently owned by hedge funds and other institutional investors.

Sage Therapeutics Trading Down 1.0 %

Shares of Sage Therapeutics stock opened at $7.19 on Wednesday. The company has a fifty day moving average price of $6.28 and a 200 day moving average price of $6.96. Sage Therapeutics, Inc. has a twelve month low of $4.62 and a twelve month high of $27.39. The stock has a market cap of $439.81 million, a price-to-earnings ratio of -1.29 and a beta of 0.94.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. Analysts forecast that Sage Therapeutics, Inc. will post -6.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SAGE has been the subject of several research analyst reports. Royal Bank of Canada upgraded Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price target for the company in a research report on Thursday, November 21st. Oppenheimer lowered their price target on Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Wednesday, October 30th. Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a research report on Wednesday, November 20th. TD Cowen lowered their price target on Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Thursday, November 21st. Finally, Truist Financial reduced their price objective on Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating on the stock in a research note on Wednesday, October 30th. Three equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Sage Therapeutics currently has an average rating of “Hold” and an average price target of $10.53.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.